Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Open Posted
- Opportunity number
- RFA-CA-27-001
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $150,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- Tribal Organizations (Not Federally Recognized)
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- For Profit Organizations
- State Governments
- Special District Governments
- Higher Education Inst. (Public)
- Small Businesses
- County Governments
- Public or Indian Housing Auth.
- City/Township Governments
- Other
- Higher Education Inst. (Private)
- 501(c)(3) Nonprofits
- Independent School Districts
- Points of contact
-
- Kelly Crotty kelly.crotty@nih.gov
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute is soliciting grant applications proposing to develop innovative technologies for analyzing, targeting, probing, handling, or quality control of biospecimens used in cancer research or clinical care, with an application due date of November 10, 2026. This opportunity funds early-stage R61 projects proposing proof-of-concept and pilot studies to test technical feasibility; applications proposing to apply or use existing technologies for hypothesis-driven research where novelty resides in the biological or clinical target are not responsive and will not be reviewed.
Eligible applicant types include higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, for-profit organizations, state and local governments, small businesses, tribal organizations and governments, independent school districts, and public or Indian housing authorities. Non-domestic entities and foreign components of U.S. organizations are eligible.
Well-suited applications must offer a high degree of technical innovation and demonstrate potential to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology, or address issues associated with cancer health disparities. Technologies proposed for development may have potential for widespread applicability but must be focused on cancer applications in this proposal.
This funding opportunity is part of the broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program and falls under CFDA 93.394 (Cancer Detection and Diagnosis Research). The source does not specify award ceilings, award floors, expected number of awards, period of performance, place of performance, cost-share requirements, or evaluation criteria weighting for this specific NOFO.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00293057.pdf | ||
| RFA-CA-27-001-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity